Citigroup (C) director records 12.5934-share dividend reinvestment
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Renee James, a director reporting through the Citigroup Inc. corporate law department, reported two non-derivative acquisitions of Common Stock on 10/01/2025. The filing shows an acquisition of 12.5934 shares at a reported price of $102.368, and a separate acquisition of 167.6309 shares at the same price. Following those transactions the reporting person is shown as beneficially owning 2,161.201 shares directly and 28,767.7021 shares indirectly. The footnotes state the smaller amount reflects reinvestment of dividend equivalents under the issuer's compensation plan for non-employee directors and the larger amount represents deferred shares held by the issuer for the reporting person’s benefit.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
James Renee Jo
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 12.593 | $102.368 | $1K |
| Grant/Award | Common Stock | 167.631 | $102.368 | $17K |
Holdings After Transaction:
Common Stock — 2,161.201 shares (Direct);
Common Stock — 28,767.702 shares (Indirect, See Footnote)
Footnotes (1)
- Reinvestment of dividend equivalents under the Issuer's Compensation Plan for Non-Employee Directors. Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors.
FAQ
What did the Citigroup (C) Form 4 filed for Renee James report?
The Form 4 reports two acquisitions on 10/01/2025: 12.5934 shares and 167.6309 shares of Citigroup common stock at $102.368 per share.
When was the Form 4 signed and by whom?
The signature block shows Renee James by Joseph B. Wollard, Attorney-in-Fact with a signature date of 10/03/2025.
Are these transactions purchases or administratively recorded allocations?
The Form 4 transaction code is reported as V and footnotes identify the entries as reinvestment of dividend equivalents and deferred shares, indicating compensation-plan allocations rather than open-market trading.